
- Remove this product from my favorite's list.
- Add this product to my list of favorites.
Products
Newsletter
![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Background
It's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.
Source
Recombinant SARS-CoV-2 S protein RBD, Fc Tag (SPD-C5255) is expressed from human 293 cells (HEK293). It contains AA Arg 319 - Phe 541 (Accession # QHD43416.1).
Predicted N-terminus: Arg 319
Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 51.5 kDa. The protein migrates as 60-65 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method.
Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Bioactivity
Please refer to product data sheet.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
(1) "Inactivation mechanism of cold plasma combined with 222 nm ultraviolet for spike protein and its application in disinfecting of SARS-CoV-2"
Sheng, Wang, Zhao et al
J Hazard Mater (2024) 465, 133458
(2) "TXM peptides inhibit SARS-CoV-2 infection, syncytia formation, and lower inflammatory consequences"
Govednik, Lainšček, Kuhar et al
Antiviral Res (2024)
(3) "Harnessing preexisting influenza virus-specific immunity increases antibody responses against SARS-CoV-2"
Dulin, Barre, Xu et al
J Virol (2024)
Showing 1-3 of 4323 papers.
Recombinant SARS-CoV-2 (COVID-19) S1 protein, His Tag (MALS verified), 100µg - 494,00 €
Recombinant Biotinylated SARS-CoV-2 (COVID-19) S protein RBD, His,Avitag™ (MALS verified), 25µg - 494,00 €
Recombinant Biotinylated SARS-CoV-2 (COVID-19) S1 protein, His,Avitag™ (MALS verified), 25µg - 494,00 €
Recombinant SARS-CoV-2 (COVID-19) Nucleocapsid protein, His Tag, 100µg - 520,00 €
Follow us